We also had a 40% rise in November prior to the Phelan-McDermid Syndrome results which were positive, but the company has been saying for some time that NNZ-2591 is the better compound, and these are open label compared to NNZ-2256 which was a blinded placebo-controlled trial in Phase-2. It shows that the preclinical data is stronger, and the company wants to accelerate the pathway to a registrational study that is placebo and double blinded. It is a bold move because the Placebo affect could impact the P3 but the company thinks the efficacy data is strong enough to warrant this for an accelerated development time.
NEU chart, page-1663
-
- There are more pages in this discussion • 363 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.27 |
Change
1.000(8.15%) |
Mkt cap ! $1.696B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.39 | $12.79 | $9.854M | 751.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2545 | $13.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.29 | 1443 | 2 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |